Evaluation of Medicinal properties and actions of Astaxanthin in Human

Analysis of Polycrest Behaviour Of Astaxanthin - NiL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2023/08/056909

Enrollment

1000

Registered

2023-08-24

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue Health Condition 2: I30-I52- Other forms of heart disease Health Condition 3: E298- Other testicular dysfunction Health Condition 4: E10- Type 1 diabetes mellitus Health Condition 5: E11- Type 2 diabetes mellitus Health Condition 6: F989- Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence

Interventions

Intervention1: Astaxanthin: Random people of age group 21-60 years is selected. They are provided with Astaxanthin 4 mg dosage twice a day along with their regular diet. To identify the general health

Eligibility

Inclusion criteria

Inclusion criteria: Healthy Human volunteers

Exclusion criteria

Exclusion criteria: pregnancy women and Humans below 18 years

Design outcomes

Primary

Measure	Time frame
General Health is improved overall the subjects involved in the trial feel Improved quality of Daily lifeTimepoint: 30 days	—

Secondary

Measure	Time frame
General Health ImprovementTimepoint: 3 months;Metabolism ImprovedTimepoint: 30 days	—

Countries

Australia, Austria, Bahrain, Barbados, Belgium, Bhutan, Bosnia and Herzegovina, Brazil, Burkina Faso, Cape Verde, Chad, Chile, China, Colombia, Congo, Cook Islands, Croatia, Czech Republic, Democratic People's Republic of Korea, Democratic Republic of the Congo, Djibouti, Ecuador, Egypt, El Salvador, Eritrea, Estonia, Ethiopia, Fiji, Finland, France, Gabon, Gambia, Georgia, Germany, Ghana, Guinea, Haiti, Hong Kong, India, Indonesia, Iran (Islamic Republic of), Ireland, Italy, Japan, Jordan, Kyrgyzstan, Latvia, Lesotho, Libyan Arab Jamahiriya, Madagascar, Malaysia, Mali, Mauritania, Micronesia (Federated States of), Netherlands, New Zealand, Nicaragua, Niger, Nigeria, Panama, Paraguay, Philippines, Portugal, Republic of Korea, Rwanda, Saint Kitts and Nevis, Sao Tome and Principe, Saudi Arabia, Singapore, Slovenia, Spain, Sri Lanka, Sudan, Switzerland, Togo, Trinidad and Tobago, Turkmenistan, United Republic of Tanzania, United States of America

Contacts

Public ContactMr Mohammed Shadab A F

Skyasta Care Health Care Pvt. Ltd

shadabshadu@yahoo.com9677012041

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026